Gilead Sciences (GILD), in freefall this morning on disappointing trial results, presents a good...

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Gilead Sciences (GILD), in freefall this morning on disappointing trial results, presents a good buying opportunity, says Deutsche Bank. DB believes a disaster scenario is unlikely and that additional data will look better, allowing Gilead to take more than 15% marketshare. DB maintains its $66 price target; GILD -18.3% to $44.79.